| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.09 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.3 | 0.09 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.076 | 0.09 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.09 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.083 | 0.1 |